Pulmonary Fibrosis

HomePatientsLung Disease Week at the ATS2015 ▶ Pulmonary Fibrosis
Pulmonary Fibrosis Week

Pulmonary Fibrosis Week

Welcome Message

Pulmonary Fibrosis Week aims to raise awareness on pulmonary fibrosis.  Pulmonary Fibrosis is characterized by excessive deposition of scar tissue in the lungs and is difficult to treat as it is often progressive, leading to poor lung function and sometimes death.  Pulmonary fibrosis can be triggered or worsened by environmental or occupational exposures: tobacco smoke, infection, drugs or be secondary to an autoimmune or inflammatory disorder.  It is estimated that idiopathic pulmonary fibrosis affects close to 200,000 people in the U.S. and 5 million worldwide with a prognosis of 50% mortality in 3-5 years.  In the last decade there has been significant progress in the understanding of idiopathic pulmonary fibrosis, with identification of gene variants associated with the disease, new biomarkers, pathways and treatment as the FDA recently approved two drugs that slow down disease progression.

The American Thoracic Society is at the forefront of efforts to improve the care, diagnosis and understanding of pulmonary fibrosis.  Within ATS, leaders in idiopathic pulmonary fibrosis research, clinical care and patient advocacy organizations collaborate to disseminate information through conferences and consensus statements to raise awareness, identify and prioritize areas of unmet need. In partnership with private foundations, medical professionals and government officials, the ATS funds research in pulmonary fibrosis that identify potential new and effective targets for therapeutic intervention.  Through these efforts, we at the ATS hope to play a significant role in transforming the diagnosis, care and management of patients with pulmonary fibrosis, eventually leading to a cure.

Naftali Kaminski, MD

Naftali Kaminski, MD
Chair, ATS Respiratory Cell & Molecular Biology Assembly
Member, ATS Board of Directors

Teresa Barnes

Teresa Barnes
Immediate Past Chair, ATS Public Advisory Roundtable

image

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of Pulmonary Fibrosis issues; and works to improve awareness of Pulmonary Fibrosis in the medical community as well as the general public. The CPF’s nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 17,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis.